During the 15th Annual Healthcare Industry Leadership Virtual Conference, our panel of Health System CEOs discussed leadership during the crisis, the impact of COVID-19 on the structure of healthcare in the United States and how the pandemic impacted innovation.
Panel Moderators:
Stuart McLean, Managing Director, A&M Healthcare Industry Group
David Shulkin, Senior Advisor, A&M Healthcare Industry Group and former Secretary of the US Department of Veterans Affairs
Speakers:
Stephen Klasko, M.D., President, Thomas Jefferson University & CEO, Jefferson Health
Paul Rothman, M.D., Dean of the Johns Hopkins University School of Medicine and CEO Of Johns Hopkins Medicine
Peter Slavin, M.D., President, Massachusetts General Hospital
Watch the other panel sessions here:
Megatrends Meet COVID-19 – Bio Pharma Business, Medical and Regulatory Perspectives
Diversity & Inclusion in Healthcare Organizations
Disruption in the ACA Market – Implications and Strategic Responses
June 11, 2025
In a recent article, A&M Healthcare Industry Group experts explore key policy changes, market dynamics, stakeholder implications and strategic actions for navigating the evolving landscape surrounding the Affordable Care Act marketplace.
The Effect of Trump’s Tariffs on the European Pharmaceutical and Biopharmaceutical Industry
June 9, 2025
As the U.S. considers imposing tariffs on European pharmaceutical imports, the ripple effects could
be felt across the global healthcare landscape.
FORMER FEDERAL HEALTH MINISTER PROFESSOR GREG HUNT JOINS ALVAREZ & MARSAL AUSTRALIA
May 27, 2025
Alvarez & Marsal appoints The Honourable Greg Hunt as a Senior Advisor bolstering its Healthcare and Public Sector advisories in support of maximizing sustainable value for clients.
Contract Research Organisations M&A Market
March 28, 2025
Rising cost pressures, stricter regulatory demands and advancements in emerging therapeutics are intensifying competition within the industry. These dynamics are fuelling the demand for greater efficiency in development lifecycles, creating significant opportunities for outsourced providers like Contract Research Organisations (CROs).
